ARS PharmaceuticalsSPRY
About: ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.
Employees: 24
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
2,238% more call options, than puts
Call options by funds: $19.2M | Put options by funds: $821K
80% more repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 25
2.42% more ownership
Funds ownership: 62.27% [Q1] → 64.69% (+2.42%) [Q2]
5% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 22
1% more funds holding
Funds holding: 113 [Q1] → 114 (+1) [Q2]
13% less capital invested
Capital invested by funds: $614M [Q1] → $533M (-$80.6M) [Q2]
33% less funds holding in top 10
Funds holding in top 10: 3 [Q1] → 2 (-1) [Q2]
Research analyst outlook
6 Wall Street Analysts provided 1 year price targets over the past 3 months
6 analyst ratings
Cantor Fitzgerald Josh Schimmer 72% 1-year accuracy 51 / 71 met price target | 76%upside $30 | Overweight Reiterated | 8 Oct 2024 |
Leerink Partners Roanna Ruiz 71% 1-year accuracy 5 / 7 met price target | 47%upside $25 | Outperform Maintained | 20 Sept 2024 |
Cantor Fitzgerald Josh Schimmer 72% 1-year accuracy 51 / 71 met price target | 76%upside $30 | Overweight Reiterated | 16 Sept 2024 |
Cantor Fitzgerald Josh Schimmer 72% 1-year accuracy 51 / 71 met price target | 76%upside $30 | Overweight Reiterated | 9 Sept 2024 |
Cantor Fitzgerald Josh Schimmer 72% 1-year accuracy 51 / 71 met price target | 76%upside $30 | Overweight Initiated | 20 Aug 2024 |
Financial journalist opinion
Based on 30 articles about SPRY published over the past 30 days
